TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06177249

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Control vaccine
Description: A group of 652 subjects were vaccinated with the control vaccine at 0, 3, 7, 14 and 28 days (5 doses in total). Blood samples were collected from the subjects at 0, 7/14 and 35/42 days for antibody detection.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Experimental vaccine
Description: A total of 652 subjects received 5 doses of the vaccine at 0, 3, 7, 14 and 28 days. Blood samples were collected on 0, 7/14 and 35/42 days for antibody detection.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Experimental vaccine
Description: A total of 652 subjects received 5 doses of the vaccine at 0, 3, 7, 14 and 28 days. Blood samples were collected on 0, 7/14 and 35/42 days for antibody detection.
Study: NCT03597412

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rosuvamibe
Description: Rosuvastatin 10mg/Ezetimibe 10mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Monorova
Description: Rosuvastatin 20mg
Study: NCT02712229

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CONNECT
Description: Primary palliative care, care management intervention led by existing oncology nurses. Deployed through a series of nurse-led encounters before or after regularly scheduled oncology visits. Based on best practices in palliative oncology care, the first visit focuses on establishing rapport, addressing symptom needs and choosing a surrogate decision maker. Subsequent visits include additional focus on treatment preferences and future goals.~Visits are guided by patient-reported outcomes. During all encounters, the nurse works with patients/caregivers to complete/update individualized Shared Care Plans. After all visits, the nurse discusses patients' symptoms, preferences and goals with their oncologists via a mandatory check-in session and a follow-up call with the patient and/or caregiver.
Study: NCT04487834

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Simethicone Solution
Description: Oral daily treatment for four weeks

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vivatlac Baby
Description: Oral daily treatment for four weeks
Study: NCT00911079

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Hyperthermia
Description: Single course of Catheter-based Ultrasound Hyperthermia (within approximately 2 hours of a Standard-of-care High Dose Rate (HDR) Brachytherapy)

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: HDR brachytherapy
Description: Completion of standard-of-care high dose rate (HDR) Brachytherapy treatments (radiation fractions) using Session #1 catheter implants
Study: NCT00501527

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Immunotherapy with modified extract of P. pratense pollen
Description: Sublingual (2 drops daily)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Immunotherapy with modified extract of P. pratense pollen
Description: Sublingual (2 drops daily)

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo 2 drops daily
Study: NCT03496181

Intervention type: BEHAVIORAL
Intervention: Multilingual Aphasia Examination
Description: For patients only prior to MRI scans.~The MAE contains eleven subtests in five categories which may be used to assess both languages in bilinguals and the participant's primary language in monolinguals: Oral Expression, Spelling, Oral Verbal Understanding, Reading, and Rating Scales. Subtests are scored for accuracy of individual items on a three-point scoring system (0, 1, 2). Contained within these domains are The Token Test, Aural Comprehension of Words and Phrases and Visual Naming which naturally parallel fMRI and direct cortical stimulation behavioral assays already in place for clinical use (phonemic fluency, auditory responsive naming and confrontation naming respectively). The MAE is expected to take under 50 minutes.

Intervention type: DIAGNOSTIC_TEST
Intervention: Language paradigms + RS fMRI
Description: 10 monolingual patients: 2 language paradigms + RS fMRI = 7x3 = 21 minutes 10 early bilingual patients: 2 language paradigms+ RS fMRI = 7x3 = 21 minutes 10 late bilingual patients: 2 language paradigms+ RS fMRI = 7x3 = 21 minutes

Intervention type: DIAGNOSTIC_TEST
Intervention: Language paradigms + RS fMRI + one anatomical sequence
Description: 10 monolingual English volunteers: 2 task language paradigms\* + 1 Resting State fMRI + one anatomical sequence for a total of approximately 25 minutes.~10 late bilingual volunteers: 4 language paradigms (2 English + 2 Spanish) + 1 Resting State fMRI + one anatomical sequence for a total of approximately 39 minutes.~10 early bilingual volunteers: 4 language paradigms (2 English + 2 Spanish) + 1 Resting State fMRI + one anatomical sequence for a total of approximately 39 minutes.
Study: NCT01725048

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mirtazapine
Description: 7.5mg by mouth once a day at night. If subject has not had a 50% or greater reduction in the PHQ-9 depression assessment score, and if the subject is not experiencing unacceptable adverse effects, then the dose may be escalated first to 15mg by mouth every night and then to 30mg by mouth every night.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Citalopram
Description: Citalopram 10mg by mouth once daily. If the subject has not had a 50% or greater reduction in PHQ-9 depression assessment score, and if the subject is not experiencing unacceptable side effects, then the dose may be escalated first to 20mg by mouth every day and then to 40mg by mouth once a day.
Study: NCT02884427

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cathode stimulation
Description: Electrical stimulation through the cathode or negative pole, in which a peripheral nerve will be subject to the passage of a direct current seeking increased excitability and conductivity during the passage of current.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Anode stimulation
Description: Electrical stimulation through the anode or positive pole, in which a peripheral rib will be subjected to the passage of a direct current seeking to reduce excitability and conductivity during the passage of current.
Study: NCT00041561

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Nitrogen gas
Description: Nitrogen gas will be given at 5ppm until Day 28 or extubation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: inhaled nitric oxide
Description: inhaled nitric oxide will be given at 5 ppm until day 28 or extubation
Study: NCT02884427

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Current application without the actual electric conduction to the person occurs. This will be achieved by adjusting parameters while installing another channel and not one that is working.
Study: NCT01024413

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: erlotinib
Description: study arm.erlotinib 150 mg oral till disease progression
Study: NCT00520104

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: intranasal ketamine
Description: drug interaction

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: intranasal ketamine
Description: drug interaction

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: intranasal ketamine
Description: drug interaction
Study: NCT03412370

Intervention type: OTHER
Intervention: Cognitive Assessment
Description: Complete cognitive assessments

Intervention type: OTHER
Intervention: Questionnaire Administration
Description: Complete questionnaires
Study: NCT03855553

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Family Based Treatment
Description: 10 families will be randomized to receive 10 - 16 weeks of Family Based Treatment (FBT), the gold standard in eating disorder treatment for adolescents. FBT is a highly structured behavioral intervention in which caregivers are charged with the primary task of re-feeding their child and normalizing his or her eating behaviors and weight status.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Enhanced Cognitive Behavioral Therapy
Description: 10 families will be randomized to receive 10 - 16 weeks of Enhanced Cognitive Behavioral Therapy (CBT-E), a clinically validated treatment for adolescent eating disorders. CBT-E is a short-term, individual treatment focused on normalizing eating behaviors and modifying underlying cognitions that contribute to the maintenance of eating disorder behaviors (e.g., over-importance of shape and weight in one's self-evaluation).
Study: NCT01890148

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD5069
Description: oral BD administration of 45 mg AZD5069
Study: NCT02020863

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Closed Loop
Description: Fluid management in the closed loop group will be performed via a closed loop (automated) system that will use an infusion pump (Q-Core) and a controller (a computer run index and algorithm developed by Sironis) to make frequent, regular and accurate adjustments to the amount of fluid the patient receives using feedback from standard operating room monitors.
Study: NCT04025723

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Downhill running
Description: 60 minutes downhill running in 10% grade, in an effort of 65% of VO2max.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Downhill running
Description: 60 minutes downhill running in 10% grade, in an effort of 65% of VO2max.
Study: NCT01491048

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: THA Physiotherapy
Description: Patients will be randomized into two groups. The control group will receive care from the team of the THA Assistance Protocol already used by the HSG of HCPA without the intervention of physiotherapy. During hospitalization, the group of cases will be submitted to physical therapy associated with the intervention of the team of the THA Assistance Protocol.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: No physiotherapy after THA
Description: No physiotherapy after THA
Study: NCT01024413

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: gefitinib
Description: study arm.gefitinib 250 mg oral till disease progression
Study: NCT01553890

Intervention type: OTHER
Group type: OTHER
Intervention: Blood sample
Description: blood sample, venous blood, about 10 ml will be drawn from participants

Intervention type: OTHER
Group type: OTHER
Intervention: Blood sample
Description: blood sample, venous blood, about 10 ml will be drawn from participants
Study: NCT01925456

Intervention type: DRUG
Group type: OTHER
Intervention: Toviaz
Description: Means of effectiveness, adherence, and utility instruments over time will be examined to evaluate whether changes are linear from baseline to 8 weeks and 3 months. We will demonstrate the validity and responsiveness of pragmatic instruments against existing established measures (Table 3).
Study: NCT01491048

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: No physiotherapy after THA
Description: No physiotherapy after THA
Study: NCT03644251

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: amniotic and umbilical cord matrix
Description: Cryopreserved human amniotic and umbilical cord product derived from donated human placental tissue following healthy, live, caesarian section, full-term births after determination of donor eligibility and placenta suitability.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: amniotic and umbilical cord matrix
Description: Cryopreserved human amniotic and umbilical cord product derived from donated human placental tissue following healthy, live, caesarian section, full-term births after determination of donor eligibility and placenta suitability.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: amniotic and umbilical cord matrix
Description: Cryopreserved human amniotic and umbilical cord product derived from donated human placental tissue following healthy, live, caesarian section, full-term births after determination of donor eligibility and placenta suitability.
Study: NCT02887807

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Single intravenous bolus of cyclosporine A (2.5 mg/kg) at the onset of resuscitation
Description: cardio-pulmonary resuscitation usual care of cardiac arrest

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Single intravenous bolus of placebo at the onset of resuscitation
Description: cardio-pulmonary resuscitation usual care of cardiac arrest
Study: NCT03872453

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zavegepant
Description: A single dose of zavegepant

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zavegepant
Description: A single dose of zavegepant

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zavegepant
Description: A single dose of zavegepant

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Zavegepant matching placebo
Description: A single dose of placebo matched to zavegepant

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Intranasal Aptar Pharma Unit Dose System
Description: A single-dose intranasal device

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Intranasal Aptar Pharma Unit Dose System
Description: A single-dose intranasal device

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Intranasal Aptar Pharma Unit Dose System
Description: A single-dose intranasal device

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Intranasal Aptar Pharma Unit Dose System
Description: A single-dose intranasal device
Study: NCT02956512

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexibuprofen
Description: Dexibuprofen 300mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexibuprofen
Description: Dexibuprofen 300mg
Study: NCT01678209

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: fMRI scans
Description: 2 fMRI scans 6-8 weeks apart

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: fMRI scans
Description: 2 fMRI scans 6-8 weeks apart

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: fMRI scans
Description: 2 fMRI scans 6-8 weeks apart

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atomoxetine arm
Description: Flexible dose titration with atomoxetine prescribed at weekly visits for 6-8 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylphenidate arm
Description: Flexible dose titration with methylphenidate for 6-8 weeks, with optional post study stabilization visits.
Study: NCT04393051

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Baricitinib Oral Tablet
Description: Baricitinib will be administered by oral route at different dosages according to age and kidney function. The drug will be administered for 14 days, unless occurrence of discontinuation criteria.
Study: NCT04694898

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Standard programme
Description: The control arm will receive national standard programme for women and children under the age of 2 years. This includes 1) national nutrition and health care including iron \& folic acid (IFA) supplementation in pregnancy; 2) early initiation and exclusive breastfeeding until 6 months of age; 3) timely introduction of liquid and semi-solid complementary foods; and 4) diversified complementary foods.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SURE intervention
Description: The SURE package includes: 1) promoting diversified agriculture; 2) promoting infant and young child feeding practices; 3) women empowerment in decision making related to agriculture, food and health; and 4) enhanced food security and Water, Sanitation and Hygiene (WASH) practices.
Study: NCT00235820

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: adalimumab
Description: 40 mg every other week following an 80 mg dose

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: MTX
Description: MTX 7.5 to 25 mg once weekly

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo adalimumab, placebo MTX
Description: placebo injections once every other week after 2 injections at Baseline (adalimumab) placebo capsules once weekly (MTX)
Study: NCT00880035

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MP3 music program listening
Description: 3 days with two 1 hour periods of headset music listening (1 day on, 1 day wash-out, 1 day off)

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MP3 music program listening
Description: 3 days with two 1 hour periods of headset music listening (1 day on, 1 day wash-out, 1 day off)
Study: NCT01481389

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Theobromine
Description: 200 ml drink with added theobromine (no cocoa added)

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Cocoa
Description: 200 ml drink with cocoa (no theobromine added)

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Cocoa and theobromine
Description: 200 ml drink with added cocoa and theobromine

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 200 ml drink (no added theobromine or cocoa)
Study: NCT00928564

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pudendal block
Description: 8ml of 0.5% bupivicaine, 1ml of 10mg/ml triamcinolone, 1ml of 8.4% sodium bicarbonate for a total volume of 10ml. Five ml will be used at each block site.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 5ml of saline at each block site.
Study: NCT02090153

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: S-1
Description: 40\~60mg bid，d1\~7 q2W

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LV
Description: LV is given simultaneously at a ﬁxed dose of 25 mg b.i.d. on days 1-7, followed by a 7 day rest.
Study: NCT02477579

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NovaCross
Description: The NovaCross™ is a guidewire positioning and support microcatheter for improving chronic total occlusion (CTO) crossability. The NovaCross™ gains its supportive characteristics through the use of a unique operator-controlled Nitinol scaffold and an extendable segment, both at its distal tip.
Study: NCT00084266

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: linezolid (Zyvox)
Description: Subjects to receive either linezolid 600 mg IV (Intravenous) or PO (orally) q 12 h (every 12 hours) for 7-14 days, except in cases of documented bacteremia where it could be extended to 21 days based upon investigator's discretion.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: vancomycin
Description: Subjects to receive vancomycin 15mg/kg IV (Intravenous) q12h (every 12 hours), adjusted for renal function, for 7-14 days, except in cases of documented bacteremia where it could be extended to 21 days based upon investigator's discretion.
Study: NCT03840850

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Personalized Risk Communication for People with Type 2 Diabetes
Description: The risk communication intervention consists of communicating the impact of being poorly controlled on two types of outcome: (1) absolute 10-year risk of experiencing a cardiovascular event, i.e. heart attack or stroke (10-year CV risk); (2) life expectancy. These personalized risk estimates are calculated based on the UKPDS outcomes model (version 2), which is a prognostic model of reference in the area of Type 2 diabetes.
Study: NCT04556643

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Breathing exercises
Description: The main components of breathing exercises during training will be as follows (A) First, fill your stomach and then your lungs with air while breathing in; (B) Feel the expansion in the stomach; (C) Make sure the muscles from your stomach to your knee are relaxed, as if you are urinating while breathing out; (D) When there is pain, perform deep abdominal breathing exercises, and take a deep breath in and hold as much as you can; (E) Try to push the baby downward; (F) You can do it by holding your breath or breathing out quite slowly from your mouth; (G) The most important point in this stage is that you should not fill up the stomach with air, and you should push downward to deliver the baby; (H) You should continue the pushing until the pain is relieved
Study: NCT01096342

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dinaciclib
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study: NCT04206592

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Oropharyngeal leak pressure during pneumoperitoneum.
Description: Oropharyngeal Leak Pressure (OLP) will be measured by closing the expiratory valve of the circle system at a fixed gas flow of 3 litres/min (maximum allowed 40 cmH2O) recording the pressure at which equilibrium has been reached or audible air is leaking.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Oropharyngeal leak pressure during pneumoperitoneum.
Description: Oropharyngeal Leak Pressure (OLP) will be measured by closing the expiratory valve of the circle system at a fixed gas flow of 3 litres/min (maximum allowed 40 cmH2O) recording the pressure at which equilibrium has been reached or audible air is leaking.